The combined company will have a portfolio of over 120 in-market products, over 185 cumulative filings pending approval and a deep pipeline of products under development for the US
Lupin has completed its acquisition of privately held US-based GAVIS Pharmaceuticals and Novel Laboratories (GAVIS). Lupin had announced the acquisition on July 23, 2015. The acquisition enhances Lupin’s scale in the US generic market and also broadens Lupin’s pipeline in dermatology, controlled substance products and other high-value and niche generics. GAVIS brings to Lupin a highly skilled US-based manufacturing and research organisation which would complement Lupin’s Coral Springs, Florida-based R&D centre for inhalation. GAVIS’s New Jersey-based manufacturing facility also becomes Lupin’s first manufacturing site in the US.
The combined company will have a portfolio of over 120 in-market products, over 185 cumulative filings pending approval and a deep pipeline of products under development for the US. The acquisition creates the fifth largest pipeline of ANDA filings with the US FDA, addressing a $63.8 billion market.
Commenting on the transaction, Vinita Gupta, Chief Executive Officer, Lupin said, “The Gavis portfolio augments our US business and niche generic pipeline. We plan to leverage the formulation expertise of Gavis to enhance both Lupin’s generic as well as specialty pipeline.”
EP News Bureau – Mumbai
Comments are closed.